The FDA has formally issued a warning letter to Novo Nordisk following the discovery of “serious violations” regarding the investigation and disclosure of adverse events linked to semaglutide, the active ingredient in blockbuster drugs Wegovy and Ozempic.
Safety reporting failures Inspection findings revealed that the company failed to comply with laws requiring the reporting of serious and unexpected medical incidents within a 15-day window. Specific violations identified include:
-
Patient fatalities: Two deaths associated with drug use were either not reported or were improperly invalidated by the company due to missing patient identifiers.
-
Mental health incidents: One suicide and one case of suicidal ideation among patients using the medication were not promptly flagged to the federal regulatory system.
-
Other complications: A disabling stroke involving an older generation drug (liraglutide) was rejected for reporting by the company after it accepted a consumer’s claim that the event was unrelated to the treatment.
Operational and procedural gaps The FDA highlighted a lack of adequate written procedures to ensure that Novo Nordisk and its contractors follow up with reporters for additional safety information. While the firm has proposed corrective actions, the agency categorized these updates as “inadequate.”
Corporate challenges This regulatory scrutiny arrives at a turbulent time for Novo Nordisk, as the company grapples with intense competition from Eli Lilly, an 11% workforce reduction, and significant turnover within its board of directors. A company spokesperson stated they intend to address the FDA’s concerns “expeditiously and holistically” to ensure full compliance with safety monitoring standards.